ch.oddb.org
 
Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
Fachinformation zu Sodipryl® retard:Sanofi SA
Vollst. FachinformationDDDDrucken 
Zusammens.Galen.FormInd./Anw.mögl.Dos./Anw.Kontraind.Warn.hinw.Interakt.Schwangerschaft
Fahrtücht.Unerw.WirkungenÜberdos.Eigensch.Pharm.kinetikPräklin.Sonstige H.Swissmedic-Nr.
PackungenReg.InhaberStand d. Info. 
C04AX21 - NaftidrofurylATC-DDD Version 2016. Source: WHO
C - Cardiovascular System

This group comprises substances used for the treatment of cardiovascular conditions.
Drugs used for the treatment of hypertension are classified in C02 - Antihypertensives, C03 - Diuretics, C07 - Beta blocking agents, C08 - Calcium channel blockers, and C09 - Agents acting on the renin-angiotensin system. For the classification of combination products of antihypertensives from different ATC groups, the following ranking should be used, from higher to lower precedence: C09, C07, C08, and C03.

C04 - Peripheral Vasodilators
 
C04A - Peripheral Vasodilators

This group comprises plain and combined preparations used in the treatment of cerebrovascular or peripheral circulatory disorders.
Combinations with Antihypertensives, see C02 - Antihypertensives.
Combinations with vasodilators used in cardiac diseases, see C01DA.

The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.

C04AX - Other Peripheral Vasodilators

Betahistine, cinnarizine and flunarizine are classified as antivertigo preparations in N07CA.
Papaverine preparations, see A03AD and G04BE.
Prostaglandin analogues used for pulmonary arterial hypertension or arteriosclerosis obliterans are classified in B01AC.

C04AX21 - Naftidrofuryl
StärkeAdm.RouteNote
 O 
2025 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home